Literature DB >> 6155797

Leukocyte migration inhibition with Epstein-Barr virus negative and positive cell extracts.

R Szigeti, L Timár, T Révész.   

Abstract

Leukocyte migration inhibition of seronegative and seropositive healthy children and that of patients with infectious mononucleosis was studied in the presence of EBV-negative and -positive cell extracts. Seronegative children showed no alteration of the leukocyte migration in the presence of the extracts. EBV-positive cell extracts caused significant migration inhibition in the group of seropositive healthy children and of IM patients. The effect was specific, since the EBV-negative cell extract had no inhibitory effect. In the acute phase of infectious mononucleosis a depressed response was observed, while after recovery the same migration inhibition could be detected. The possible cause of the depressed cell-mediated immune response in the acute phase of the disease is discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6155797     DOI: 10.1111/j.1398-9995.1980.tb01723.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  3 in total

1.  A prospective study on infectious mononucleosis in childhood--symptoms, serology, Epstein-Barr-Virus specific leukocyte migration inhibition.

Authors:  L Timár; J Budai; M Koller
Journal:  Infection       Date:  1982       Impact factor: 3.553

Review 2.  Epstein-Barr virus (EBV)-specific cell-mediated and humoral immune responses in ataxia-telangectasia patients.

Authors:  G Masucci; I Berkel; M G Masucci; I Ernberg; R Szigeti; F Ersoy; O Sanal; O Yegin; G Henle; W Henle
Journal:  J Clin Immunol       Date:  1984-09       Impact factor: 8.317

3.  Detection of an Epstein-Barr virus-associated membrane antigen in Epstein-Barr virus-transformed nonproducer cells by leukocyte migration inhibition and blocking antibody.

Authors:  R Szigeti; D Sulitzeanu; G Henle; W Henle; G Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.